{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T01:32:56Z","timestamp":1772155976678,"version":"3.50.1"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To compare the outcomes of women with stage III uterine cancer treated with chemotherapy alone, external beam radiation alone, and combination chemotherapy and radiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>The National Cancer Database was used to identify women with stage III endometrioid, serous, and clear cell uterine cancer treated with either chemotherapy (with or without vaginal brachytherapy) alone, external beam radiation (with or without brachytherapy), or combination chemotherapy and external beam radiation (with or without vaginal brachytherapy) from 2004 to 2015. Survival was estimated using Cox proportional hazards models and adjusted survival curves after propensity score analysis using inverse probability of treatment weighting to balance the clinical and demographic characteristics between the cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Of the 20,873 patients identified, 9,456 (45.3%) received chemotherapy alone, 2,417 (11.6%) were treated with radiation alone, and 9,000 (43.1%) received chemotherapy in combination with external beam radiation. Use of combination therapy was 33.0% in 2004, and then rose to 50.5% in 2015. The mortality of the cohort was 33.1% and median survival was 115 months. Within the cohort, combination therapy was associated with a 23% reduction in mortality (hazard ratio [HR]=0.77; 95% CI 0.73\u20130.80) compared with chemotherapy alone. Similar findings of decreased mortality were noted in subgroup analyses for both stage IIIA (HR=0.81; 95% CI 0.68\u20130.98) and stage IIIC (HR=0.79; 95% CI 0.75\u20130.84) tumors. Similarly, when compared with radiation alone, combination therapy was accompanied by a 19% decrease in mortality (HR=0.81; 95% CI 0.73\u20130.89). Combination chemoradiation was associated with decreased mortality across all of the histologic subtypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Among women with stage III uterine cancer, combination chemotherapy and external beam radiation is associated with decreased mortality compared with chemotherapy or radiation alone.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000003287","type":"journal-article","created":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T21:00:46Z","timestamp":1560286846000},"page":"17-29","source":"Crossref","is-referenced-by-count":11,"title":["Chemotherapy, Radiation, or Combination Therapy for Stage III Uterine Cancer"],"prefix":"10.1097","volume":"134","author":[{"given":"Sbaa","family":"Syeda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"June Y.","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana I.","family":"Tergas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fady","family":"Khoury-Collado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Melamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caryn M.","family":"St. Clair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cande V.","family":"Ananth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred I.","family":"Neugut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn L.","family":"Hershman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason D.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230711","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R2-20230711","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ijrobp.2018.05.034","article-title":"Defining the place of adjuvant chemotherapy and radiation for high-risk endometrial cancer from recent randomized clinical trials: some answers, more questions","volume":"102","author":"Albuquerque","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R3-20230711","doi-asserted-by":"crossref","first-page":"218.e1","DOI":"10.1016\/j.ajog.2007.08.075","article-title":"Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths","volume":"198","author":"Ueda","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"R5-20230711","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ygyno.2009.04.013","article-title":"FIGO stage IIIC endometrial carcinoma: prognostic factors and outcomes","volume":"114","author":"Hoekstra","year":"2009","journal-title":"Gynecol Oncol"},{"key":"R6-20230711","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/COC.0b013e31829c12be","article-title":"Survival analysis of cancer patients with FIGO stage IIIA endometrial cancer","volume":"38","author":"Lum","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"R8-20230711","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.3802\/jgo.2017.28.e74","article-title":"Highlights from the gynecologic oncology track at the 2017 annual meeting of the American Society of Clinical Oncology","volume":"28","author":"Wolford","year":"2017","journal-title":"J Gynecol Oncol"},{"key":"R10-20230711","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1245\/s10434-007-9747-3","article-title":"The National Cancer Data Base: a powerful initiative to improve cancer care in the United States","volume":"15","author":"Bilimoria","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"R11-20230711","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1002\/sim.1903","article-title":"Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study","volume":"23","author":"Lunceford","year":"2004","journal-title":"Stat Med"},{"key":"R12-20230711","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cmpb.2003.10.004","article-title":"Adjusted survival curves with inverse probability weights","volume":"75","author":"Cole","year":"2004","journal-title":"Computer Methods Programs Biomed"},{"key":"R13-20230711","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/aje\/kwn164","article-title":"Constructing inverse probability weights for marginal structural models","volume":"168","author":"Cole","year":"2008","journal-title":"Am J Epidemiol"},{"key":"R14-20230711","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1002\/sim.7084","article-title":"Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis","volume":"35","author":"Austin","year":"2016","journal-title":"Stat Med"},{"key":"R15-20230711","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/14737140.2019.1531708","article-title":"Adjuvant therapy for high-risk endometrial cancer: recent evidence and future directions","volume":"19","author":"De Boer","year":"2019","journal-title":"Expert Rev Anticancer Ther"},{"key":"R16-20230711","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ygyno.2015.06.030","article-title":"A multicenter analysis of adjuvant therapy after surgery for stage IIIC endometrial adenocarcinoma: a Korean Radiation Oncology Group study (KROG 13-17)","volume":"138","author":"Yoon","year":"2015","journal-title":"Gynecol Oncol"},{"key":"R17-20230711","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1200\/JCO.2004.00.7617","article-title":"Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study","volume":"24","author":"Randall","year":"2006","journal-title":"J Clin Oncol"},{"key":"R18-20230711","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s10147-010-0081-6","article-title":"Concomitant postoperative radiation and chemotherapy following surgery was associated with improved overall survival in patients with FIGO stages III and IV endometrial cancer","volume":"15","author":"Nakayama","year":"2010","journal-title":"Int J Clin Oncol"},{"key":"R19-20230711","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ygyno.2016.07.091","article-title":"Utilization of adjuvant therapies and their impact on survival for women with stage IIIC endometrial adenocarcinoma","volume":"142","author":"Wong","year":"2016","journal-title":"Gynecol Oncol"},{"key":"R20-20230711","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.3802\/jgo.2018.29.e49","article-title":"Value of combined adjuvant chemotherapy and radiation on survival for stage III uterine cancer: is less radiation equal to more?","volume":"29","author":"Wang","year":"2018","journal-title":"J Gynecol Oncol"},{"key":"R21-20230711","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ygyno.2012.10.010","article-title":"A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer","volume":"128","author":"Secord","year":"2013","journal-title":"Gynecol Oncol"},{"key":"R22-20230711","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/sj.bjc.6603279","article-title":"Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial","volume":"95","author":"Maggi","year":"2006","journal-title":"Br J Cancer"},{"key":"R23-20230711","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1470-2045(18)30079-2","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial","volume":"19","author":"de Boer","year":"2018","journal-title":"Lancet Oncol"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006250-201907000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T15:12:28Z","timestamp":1689088348000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006250-201907000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000003287","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735978177.793563183","asserted-by":"object"}]},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}